News & Events
Crinetics Announces October 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 619,100 shares of its common stock to eleven new...
READ MORECantor Global Healthcare Conference 2023
Event Date: September 26, 2023
READ MORECrinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
Crinetics management will participate in a fireside chat and conduct investor meetings at the Cantor Global Healthcare Conference on September...
READ MORECrinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Crinetics intends to use the net proceeds from the offering to fund the development of paltusotine, CRN04894 and its other...
READ MORECrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics announced today that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares...
READ MORECrinetics Topline Results from Paltusotine Phase 3 PATHFNDR-1 Study
Event Date: September 11, 2023
READ MORECrinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
Crinetics Pharmaceuticals reports that paltusotine, an oral, once-daily investigational compound, met the primary endpoint and all secondary endpoints of the...
READ MORECrinetics Announces September 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces September 2023 inducement grants: the stock options were granted as inducements material to nine employees entering into...
READ MORECrinetics Announces August 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces August 2023 inducement grants: the stock options were granted as inducements material to seven employees entering into...
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals reported financial results and provided an update on second quarter 2023 progress
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
